CRISPR Therapeutics (CRSP) News Today → Log Into Marc's $5,000 System Today (From Chaikin Analytics) (Ad) Free CRSP Stock Alerts $54.84 -0.40 (-0.72%) (As of 05/28/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 28 at 2:21 PM | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0%CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0%May 27 at 5:28 PM | marketbeat.comContrarius Investment Management Ltd Sells 37,808 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Contrarius Investment Management Ltd decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 17.1% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 182,927 shares of the company's stock after selling 37,808 sharesMay 27 at 12:32 PM | investorplace.com7 Biotech Stocks to Put on Your Breakthrough RadarMay 27 at 12:20 PM | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.9% CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.9%May 26 at 9:15 AM | fool.com3 Reasons to Buy CRISPR Therapeutics Stock Like There's No TomorrowMay 25 at 2:14 AM | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.2% After Analyst DowngradeMay 24, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 0.2% on Analyst DowngradeCRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.2% Following Analyst DowngradeMay 24, 2024 | americanbankingnews.comCitigroup Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $84.00May 24, 2024 | marketbeat.comBNP Paribas Financial Markets Cuts Stake in CRISPR Therapeutics AG (NASDAQ:CRSP)BNP Paribas Financial Markets lessened its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 67.3% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 42,290 shares of the company's stock after sMay 24, 2024 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 3.1% on Analyst DowngradeMay 23, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 3.1% Following Analyst DowngradeCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 3.1% After Analyst DowngradeMay 23, 2024 | globenewswire.comCRISPR Therapeutics Strengthens Executive Leadership Team with Key AppointmentsMay 23, 2024 | investorplace.comThe 2030 Millionaire's Club: 3 Biotech Stocks to Buy NowMay 22, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Up 6%CRISPR Therapeutics (NASDAQ:CRSP) Shares Up 6%May 22, 2024 | investorplace.com7 Must-Buy Stocks if You Only Have $1,000 to Spend: May EditionMay 22, 2024 | fool.comIs CRISPR Therapeutics a Millionaire Maker?May 22, 2024 | fool.comBull Market Buys: 2 Growth Stocks to Own for the Long RunMay 21, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1.5%CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 1.5%May 21, 2024 | marketbeat.comTrexquant Investment LP Acquires New Position in CRISPR Therapeutics AG (NASDAQ:CRSP)Trexquant Investment LP acquired a new stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 132,385 shares of theMay 20, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Acquires 15,085 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)Charles Schwab Investment Management Inc. lifted its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2.4% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 653,023 shares of the company's stock after buying an additional 1May 19, 2024 | americanbankingnews.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.3%May 18, 2024 | uk.finance.yahoo.comCRSP May 2024 39.000 putMay 17, 2024 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by Nikko Asset Management Americas Inc.Nikko Asset Management Americas Inc. lowered its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 2.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,369,762 shares of the company'sMay 17, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Down 0.3% CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 0.3%May 17, 2024 | fool.comIs CRISPR Therapeutics Stock a Buy?May 17, 2024 | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of "Hold" from BrokeragesCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) has earned a consensus rating of "Hold" from the seventeen ratings firms that are presently covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a sell recommendation, seven have given a holdMay 16, 2024 | marketbeat.comFarrow Financial Inc. Acquires Shares of 18,920 CRISPR Therapeutics AG (NASDAQ:CRSP)Farrow Financial Inc. bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm bought 18,920 shares of the company's stock, valued at approximately $1,184,000. Several other hedgMay 16, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.7%CRISPR Therapeutics (NASDAQ:CRSP) Shares Down 2.7%May 16, 2024 | investorplace.com7 No-Brainer Stocks to Buy and Hold for the Next 20 Years: May 2024May 15, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 2.2%CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 2.2%May 15, 2024 | seekingalpha.comCRISPR Therapeutics AG (CRSP) BofA Securities 2024 Health Care Conference (Transcript)May 15, 2024 | fool.comIs CRISPR Stock Going to $95? 1 Wall Street Analyst Thinks So.May 14, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4%CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 3.4%May 14, 2024 | fool.com2 Healthcare Stocks to Buy and Hold for Great Long-Term PotentialMay 13, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Shares Up 11.3%CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Up 11.3%May 13, 2024 | investorplace.comThe 3 Best Cathie Wood Stocks to Buy in May 2024May 13, 2024 | markets.businessinsider.comStifel Nicolaus Sticks to Their Hold Rating for Crispr Therapeutics AG (CRSP)May 13, 2024 | marketbeat.comSwiss National Bank Has $9.31 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Swiss National Bank decreased its stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 9.8% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 148,700 shares of the company's stock afteMay 11, 2024 | marketbeat.comReynders McVeigh Capital Management LLC Has $5.76 Million Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Reynders McVeigh Capital Management LLC raised its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 20.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 92,048 shares of the company's stock after purchasMay 11, 2024 | finance.yahoo.comBroker Revenue Forecasts For CRISPR Therapeutics AG (NASDAQ:CRSP) Are Surging HigherMay 11, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in May 2024May 10, 2024 | finance.yahoo.comCRISPR Therapeutics AG Reports Q1 2024 Earnings: Misses Analyst Net Income ForecastMay 10, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Price Target Cut to $95.00Oppenheimer decreased their price target on shares of CRISPR Therapeutics from $102.00 to $95.00 and set an "outperform" rating for the company in a research note on Friday.May 10, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Trading Down 2.1% After Analyst DowngradeCRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 2.1% After Analyst DowngradeMay 10, 2024 | finance.yahoo.comWe're Interested To See How CRISPR Therapeutics (NASDAQ:CRSP) Uses Its Cash Hoard To GrowMay 10, 2024 | marketbeat.comFY2025 EPS Estimates for CRISPR Therapeutics AG Lowered by Analyst (NASDAQ:CRSP)CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Brookline Capital Management cut their FY2025 earnings estimates for CRISPR Therapeutics in a research report issued on Wednesday, May 8th. Brookline Capital Management analyst L. Cann now expects that the company will poMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Crispr Therapeutics AG on Strong Pipeline and Financial HealthMay 9, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Receives Market Outperform Rating from JMP SecuritiesJMP Securities reaffirmed a "market outperform" rating and set a $86.00 price objective on shares of CRISPR Therapeutics in a report on Thursday.May 9, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) Announces Earnings ResultsCRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) announced its earnings results on Wednesday. The company reported ($1.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.35) by ($0.08). The firm had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. The business's revenue for the quarter was down 99.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.67) earnings per share.May 9, 2024 | marketbeat.comCRISPR Therapeutics (NASDAQ:CRSP) PT Lowered to $65.00 at Wells Fargo & CompanyWells Fargo & Company cut their price target on shares of CRISPR Therapeutics from $70.00 to $65.00 and set an "equal weight" rating for the company in a report on Thursday. Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address WARNING about the death of the U.S. dollar… (Ad)Where do you turn during times of economic uncertainty? Many elites trust storing their wealth in gold (which has historically boomed when the dollar’s value has plummeted!) Get Colonial Metals' new Precious Metals Investment Guide. CRSP Media Mentions By Week CRSP Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.780.89▲Average Medical News Sentiment CRSP News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼229▲CRSP Articles Average Week Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Allogene Therapeutics News Fate Therapeutics News Adverum Biotechnologies News Cellectis News Sangamo Therapeutics News bluebird bio News Precision BioSciences News Neurocrine Biosciences News Bio-Techne News Qiagen News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRSP) was last updated on 5/28/2024 by MarketBeat.com Staff From Our PartnersDigitizing the $11T commodities sector with one tiny stockResource Stock DigestNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsHe Is Giving Away BitcoinCrypto Swap ProfitsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersElon’s New Device is About to Shock the WorldInvestorPlaceMissed NVDA? Buy this AI stock NOWChaikin AnalyticsThe #1 Crypto That You Don’t Own… YetCrypto 101 MediaTim Sykes’ Urgent Trade Alert: “Make this move now”Timothy Sykes Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
